MYA, the innovative diagnostics platform for the full mapping of personal allergies

Projektinformationen

MYA

ID Finanzhilfevereinbarung: 728239

DOI 10.3030/728239

Abgeschlossenes Projekt

EK-Unterschriftsdatum 4 Mai 2016

Startdatum 1 Juni 2016

Enddatum 30 September 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

ALLTOX S.R.L.
Italy

Ziel

Allergies are chronic conditions caused by an extreme immune response to inhalant and food allergens that affect today 500 million (M) individuals worldwide and 150 M in Europe. International institutions all agree in the benefits that early allergy diagnosis and targeted treatment could bring to society. However, only 5% of the population gets a proper diagnosis, either due to limited awareness or scarcity of allergy specialists. Thus, patients try to self-manage their condition and non-specialists prescribe inadequate treatments. Therefore, the patient’s quality of life could be improved if allergy diagnosis were made accessible to the general public. Also, € 30 M/year would be saved in Europe by enhancing the efficiency of our healthcare system.
In response, ALLTOX has created MYA (Map Your Allergies), a high quality, cost-effective test for allergy screening. Our 40-plex array-based technology will serve to quantitatively detect the patient’s immunoglobulin IgE, which are produced by the immune system upon contact with a particular allergen. The personal allergy profile can be obtained and thus, facilitate an adequate management.
MYA will be offered to the general public at an affordable price through a network of pharmacies and primary care centres, who will collect the sample and ship it to our selected laboratories to run the analysis. In only 3 days, a full report and personalized advice will be conveniently available to the patient through our website, greatly reducing the current time-to-diagnosis (8 weeks).
Our product entails a cost-effective diagnostic test that will facilitate detection of allergy risk and provision of adequate management to those patients suffering from this chronic disease. Also, the MYA test will help to relieve the costly impact incurred by allergies on our ready saturated healthcare system. In turn, MYA will provide ALLTOX estimated cumulative revenues of €40.2 M after selling 420 000 units within five years from market launch.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › allergology › food allergy
• medical and health sciences › clinical medicine › pneumology › asthma
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › basic medicine › immunology
• medical and health sciences › health sciences › health care services

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

ALLTOX S.R.L.

• Netto-EU-Beitrag: € 50 000,00
• Adresse: VIA SARDEGNA 38 ; 20146 MILANO ; Italien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Nord-Ovest › Lombardia › Milano
• Region: Nord-Ovest › Lombardia › Milano
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00